Processing

Please wait...

Settings

Settings

Goto Application

1. WO2015157409 - MITOCHONDRIA-TARGETING PLATINUM(IV) PRODRUG

Publication Number WO/2015/157409
Publication Date 15.10.2015
International Application No. PCT/US2015/024909
International Filing Date 08.04.2015
IPC
A61K 31/282 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
28Compounds containing heavy metals
282Platinum compounds
CPC
A61K 31/282
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
28Compounds containing heavy metals
282Platinum compounds
A61K 31/555
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
555containing heavy metals, e.g. hemin, hematin, melarsoprol
A61K 33/243
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
33Medicinal preparations containing inorganic active ingredients
24Heavy metals; Compounds thereof
243Platinum; Compounds thereof
A61K 47/54
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51the non-active ingredient being a modifying agent
54the modifying agent being an organic compound
A61K 47/6923
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
69the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
6921the form being a particulate, a powder, an adsorbate, a bead or a sphere
6923the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
A61K 47/6929
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
69the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
6921the form being a particulate, a powder, an adsorbate, a bead or a sphere
6927the form being a solid microparticle having no hollow or gas-filled cores
6929the form being a nanoparticle, e.g. an immuno-nanoparticle
Applicants
  • UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. [US]/[US]
Inventors
  • DHAR, Shanta
  • PATHAK, Rakesh
  • MARRACHE, Sean
Agents
  • CAMPBELL, Keith
Priority Data
61/976,55908.04.2014US
PCT/US2014/06999712.12.2014US
PCT/US2015/01872004.03.2015US
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) MITOCHONDRIA-TARGETING PLATINUM(IV) PRODRUG
(FR) PROMÉDICAMENT À BASE DE PLATINE (IV) CIBLANT LES MITOCHONDRIES
Abstract
(EN) Pt(IV) compounds include a mitochondria targeting moiety. One example of a Pt(IV) compound having a mitochondria targeting moiety is a Pt(IV) cisplatin-based compound. Upon reduction, the mitochondrial targeting moieties are released resulting in a Pt(II) therapeutic agent. Pt(IV) compounds including a mitochondria targeting moiety can be included in nanoparticles. The compounds or nanoparticles can be used to treat, for example, cancer.
(FR) Les composés à base de Pt(IV) comprennent une fraction de ciblage des mitochondries. Un exemple d'un composé à base de Pt(IV) ayant une fraction de ciblage des mitochondries est un composé à base de Pt(IV) cisplatine. Lors de la réduction, les fractions de ciblage des mitochondries sont libérées, résultant en un agent thérapeutique Pt(II). Les composés à base de Pt(IV) comprenant une fraction de ciblage des mitochondries peuvent être inclus dans des nanoparticules. Les composés ou nanoparticules peuvent être utilisés pour traiter, par exemple, le cancer.
Related patent documents
Latest bibliographic data on file with the International Bureau